- Report
- December 2024
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- October 2024
- 138 Pages
Global
From €3803EUR$4,000USD£3,195GBP
- Report
- September 2024
- 152 Pages
Global
From €2139EUR$2,250USD£1,797GBP
- Report
- October 2024
- 189 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 196 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- November 2024
- 150 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- July 2024
- 139 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- March 2025
- 93 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 182 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 194 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- January 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- December 2024
- 200 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- June 2024
- 231 Pages
Global
From €4749EUR$4,995USD£3,989GBP
- Report
- June 2024
- 52 Pages
North America
From €5699EUR$5,995USD£4,788GBP
- Report
- June 2024
- 66 Pages
Europe
From €5699EUR$5,995USD£4,788GBP
- Report
- June 2024
- 69 Pages
Asia Pacific
From €5699EUR$5,995USD£4,788GBP
- Report
- June 2024
- 30 Pages
United States
From €4749EUR$4,995USD£3,989GBP

Transcatheter Mitral Valve Repair (TMVR) is part of the broader cardiovascular devices market, specifically addressing the treatment of mitral valve disease through a minimally invasive surgical approach. TMVR offers an alternative to traditional open-heart surgery by using a catheter to deliver repair devices such as clips or implants to the affected valve. This method is particularly useful for patients who are deemed high-risk for surgery due to comorbidities or other factors. The market for TMVR has expanded due to technological advancements, increasing prevalence of mitral regurgitation, and a growing preference for less invasive procedures among both patients and healthcare providers. The development of innovative devices is fueled by clinical research and trials aimed at improving patient outcomes and expanding the treatable patient population.
Within the TMVR market, several companies have emerged as key players. These include Abbott Laboratories, known for its MitraClip system; Edwards Lifesciences, which has been developing its own mitral repair technology; Medtronic, with investments in mitral valve repair devices; and Boston Scientific, exploring the space through acquisitions and development of its own solutions. Other entrants and start-ups continue to invest in research and development to provide new and improved options for TMVR. Show Less Read more